指南与共识骨质疏松与代谢性骨病小儿骨科创伤骨科

低磷酸酯酶症:加拿大诊断与管理更新

Hypophosphatasia: Canadian update on diagnosis and management.
指南 / 共识 · Osteoporos Int · 2019-03-26

本文为加拿大立场文件,基于MEDLINE、EMBASE和Cochrane数据库检索及文献综述,结合最高级别证据与专家意见形成共识推荐,概述低磷酸酯酶症(HPP)在儿童和成人中的诊断与管理,指出药物治疗可带来显著临床改善。

要点

  • HPP由ALPL基因功能丧失突变导致组织非特异性碱性磷酸酶活性降低。
  • 碱性磷酸酶不足使无机焦磷酸等矿化抑制物升高,导致骨骼和牙齿矿化受损。
  • 临床可表现为乳牙早失、跖骨及股骨转子下骨折、脆性骨折及骨愈合不良。

核心结论

  • HPP与显著的患病率和死亡率相关,药物治疗可带来显著的临床改善。

研究设计与样本

  • 加拿大立场文件,通过MEDLINE、EMBASE和Cochrane数据库检索及文献综述,基于最高级别证据与专家意见形成共识推荐。

主要发现

  • HPP由ALPL基因功能丧失突变引起组织非特异性碱性磷酸酶(TNSALP)活性降低。
  • 碱性磷酸酶水平不足导致矿化抑制物升高,主要为无机焦磷酸。
  • 骨骼矿化受损可导致血清钙和磷升高。
  • 临床特征包括乳牙早失、跖骨和股骨转子下骨折以及脆性骨折,观察到此骨折后骨愈合不良。
  • 肌痛和肌无力也可能出现;婴儿期和儿童期可发生呼吸和神经系统并发症。

关键数值与推荐

  • 对符合治疗标准的个体需仔细评估并考虑药物干预。

临床怎么用

  • 对符合治疗标准的个体,考虑药物干预。

局限性

  • 儿童和成人表现差异极大,自然史了解甚少,尤其是成人。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Hypophosphatasia (HPP) is a rare inherited disorder of bone and mineral metabolism caused by loss of function mutations in the ALPL gene. The presentation in children and adults can be extremely variable and natural history is poorly understood particularly in adults. Careful patient evaluation is required with consideration of pharmacologic intervention in individuals meeting criteria for therapy. INTRODUCTION: The purposes of this review are to present current evidence regarding the diagnosis and management of hypophosphatasia in children and adults and provide evidence-based recommendations for management. METHOD: A MEDLINE, EMBASE, and Cochrane database search and literature review was completed. The following consensus recommendations were developed based on the highest level of evidence as well as expert opinion. RESULTS: Hypophosphatasia is a rare inherited disorder of bone and mineral metabolism due to loss of function mutations in the tissue non-specific alkaline phosphatase (ALPL) gene causing reductions in the activity of the tissue non-specific isoenzyme of alkaline phosphatase (TNSALP). Deficient levels of alkaline phosphatase result in elevation of inhibitors of mineralization of the skeleton and teeth, principally inorganic pyrophosphate. The impaired skeletal mineralization may result in elevations in serum calcium and phosphate. Clinical features include premature loss of teeth, metatarsal and subtrochanteric fractures as well as fragility fractures. Poor bone healing post fracture has been observed. Myalgias and muscle weakness may also be present. In infancy and childhood, respiratory and neurologic complications can occur. CONCLUSIONS: HPP is associated with significant morbidity and mortality. Pharmacologic intervention can result in significant clinical improvement. This Canadian position paper provides an overview of the musculoskeletal, renal, dental, respiratory, and neurologic manifestations of hypophosphatasia. The current state of the art in the diagnosis and management of hypophosphatasia is presented.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Khan AA, Josse R, Kannu P, et al. Hypophosphatasia: Canadian update on diagnosis and management. Osteoporos Int. 2019. PMID: 30915507. doi:10.1007/s00198-019-04921-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。